Targeted Protein Degradation and Metabolic Inhibition as Complementary Therapeutic Strategies: TEAD PROTACs and NAT8L Inhibitors in Oncology

Anna C. Renner, Robert B. Kargbo

Open source

DOI
10.1021/acsmedchemlett.6c00255
Published
2026-05-25
Container
ACS Medicinal Chemistry Letters
Publisher
American Chemical Society (ACS)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1021/acsmedchemlett.6c00255,
  title = {Targeted Protein Degradation and Metabolic Inhibition as Complementary Therapeutic Strategies: TEAD PROTACs and NAT8L Inhibitors in Oncology},
  author = {Anna C. Renner and Robert B. Kargbo},
  year = {2026},
  journal = {ACS Medicinal Chemistry Letters},
  doi = {10.1021/acsmedchemlett.6c00255},
  url = {https://doi.org/10.1021/acsmedchemlett.6c00255}
}

RIS

TY  - JOUR
TI  - Targeted Protein Degradation and Metabolic Inhibition as Complementary Therapeutic Strategies: TEAD PROTACs and NAT8L Inhibitors in Oncology
AU  - Anna C. Renner
AU  - Robert B. Kargbo
PY  - 2026
JO  - ACS Medicinal Chemistry Letters
DO  - 10.1021/acsmedchemlett.6c00255
UR  - https://doi.org/10.1021/acsmedchemlett.6c00255
ER  - 

APA

Renner, A. C., & Kargbo, R. B. (2026). Targeted Protein Degradation and Metabolic Inhibition as Complementary Therapeutic Strategies: TEAD PROTACs and NAT8L Inhibitors in Oncology. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/acsmedchemlett.6c00255

Source records